Literature DB >> 14716347

Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation.

T K Marras1, C K Chan, J H Lipton, H A Messner, J P Szalai, A Laupacis.   

Abstract

We studied long-term pulmonary function testing (PFT) in a retrospective cohort of 6-month survivors of allogeneic marrow transplant (BMT) between 1980 and 1997. Of 593 patients, 73, 71 and 65% had adequate data to assess for obstruction, restriction and diffusion impairments respectively. Over 5 years, mean declines in 1-s forced expiratory volume/forced vital capacity (FEV1/FVC), total lung capacity (TLC) and diffusion were 4, 7 and 17%, respectively. TLC and diffusion tended to subsequently increase. In all, 6, 12 and 35% of patients met criteria for obstruction, restriction and impaired diffusion, respectively. Obstruction was less common in recent transplants (5 vs 15%, P=0.004), while restriction and diffusion impairment rates remained stable. There was significantly greater mortality with obstruction (HR 2.0 (1.04-3.95)), and a nonstatistically significant higher mortality rate with restriction (HR 1.6 (0.95-2.75)), but not with impaired diffusion (HR=0.99 (0.65-1.50)). cGVHD (OR 16.7 (2.2-129.8)) and busulfan (OR 2.9 (1.01-8.24)) were associated with obstruction. Marrow from nonsibling or mismatched donors (OR 4.9 (2.2-10.7)) was associated with restriction. In summary, after BMT, decreased diffusion capacity is common and benign; obstruction has decreased in frequency, is rare without cGVHD, and is associated with mortality; nonsibling and mismatched donor are risk factors for restriction.

Entities:  

Mesh:

Year:  2004        PMID: 14716347     DOI: 10.1038/sj.bmt.1704377

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

1.  Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant.

Authors:  A L Oh; P Patel; K Sweiss; R Chowdhery; S Dudek; D Rondelli
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

Review 2.  Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

Authors:  Rachel Phelan; Hesham Eissa; Kerri Becktell; Neel Bhatt; Matthew Kudek; Brandon Nuechterlein; Lauren Pommert; Ryuma Tanaka; K Scott Baker
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

3.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Authors:  Kirsten M Williams; Guang-Shing Cheng; Iskra Pusic; Madan Jagasia; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Jason W Chien; David A Jacobsohn; Steven Z Pavletic; Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Xiaoyu Chai; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-22       Impact factor: 5.742

4.  Lung function before and after pediatric allogeneic hematopoietic stem cell transplantation: a predictive role for DLCOa/VA.

Authors:  Troy C Quigg; Young-Jee Kim; W Scott Goebel; Paul R Haut
Journal:  J Pediatr Hematol Oncol       Date:  2012-05       Impact factor: 1.289

5.  Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study.

Authors:  Hesham M Eissa; Lu Lu; Malek Baassiri; Nickhill Bhakta; Matthew J Ehrhardt; Brandon M Triplett; Daniel M Green; Daniel A Mulrooney; Leslie L Robison; Melissa M Hudson; Kirsten K Ness
Journal:  Blood Adv       Date:  2017-11-07

6.  Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.

Authors:  Brandon K C Au; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

7.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

8.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

Review 9.  Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.

Authors:  Jason W Chien; Steven Duncan; Kirsten M Williams; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-05       Impact factor: 5.742

10.  Repair of impaired pulmonary function is possible in very-long-term allogeneic stem cell transplantation survivors.

Authors:  Natasha A Jain; Priyanka A Pophali; Jeffrey K Klotz; Sawa Ito; Eleftheria Koklanaris; Kamna Chawla; Christopher S Hourigan; Nicole Gormley; Bipin N Savani; Austin John Barrett; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.